ArticleAnaerobe2013
Community-associated Clostridium difficile infection: how real is it?
Article in Anaerobe, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 46 citations in OpenAlex.
- Article
- Bezlotoxumab in Patients with a PrimaryAntibiotics (Basel, Switzerland) · 2022Article
- Fidaxomicin for the Treatment ofAntibiotics (Basel, Switzerland) · 2022Review
- Review
- Association of Household Exposure to Primary Clostridioides difficile Infection With Secondary Infection in Family Members.JAMA network open · 2020Article
- Review
- Community Environmental Contamination of ToxigenicOpen forum infectious diseases · 2017Article
- Epidemiology and Risk Factors for Community-Associated Clostridium difficile Infection: A Narrative Review.Infectious diseases and therapy · 2016Review
- Clostridium difficile infection in a French university hospital: Eight years of prospective surveillance study.Medicine · 2016Observational
- Predominance and high antibiotic resistance of the emerging Clostridium difficile genotypes NAPCR1 and NAP9 in a Costa Rican hospital over a 2-year period without outbreaks.Emerging microbes & infections · 2016Article
- Association Between Outpatient Antibiotic Prescribing Practices and Community-Associated Clostridium difficile Infection.Open forum infectious diseases · 2015Article
- C. difficile Infection: Changing Epidemiology and Management Paradigms.Clinical and translational gastroenterology · 2015Article
- Flooding and Clostridium difficile Infection: A Case-Crossover Analysis.International journal of environmental research and public health · 2015Article
- Ambulatory-treated Clostridium difficile infection: a comparison of community-acquired vs. nosocomial infection.Epidemiology and infection · 2015Article
- A possible route for foodborne transmission of Clostridium difficile?Foodborne pathogens and disease · 2015Review
- The epidemiology of Clostridium difficile infection inside and outside health care institutions.Infectious disease clinics of North America · 2015Review
- NAP1 strain type predicts outcomes from Clostridium difficile infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014Article
- Clostridium difficile infection: management strategies for a difficult disease.Therapeutic advances in gastroenterology · 2014Review
- Epidemiology of Clostridium difficile infection.Journal of pharmacy practice · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Community-associated Clostridium difficile infection (CA-CDI) represents 32% of all CDI cases based on U.S. population-based data. The current epidemic strain, NAP1, is the most prevalent strain causing these infections. Although complications, recurrence and death are uncommon, one-fourth of the CA-CDI patients are hospitalized within 7 days after the diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.